Serological methods
Serological methods
Guo Shuang1, Yinggai Song1, Paul E. Verweij2
1Department of Dermatology, Peking University First Hospital, Peking University, Beijing, China; 2Center of Expertise for Mycology of Radboud University Medical Center, Nijmegen, The Netherlands
Antigen detection
Cryptococcal Antigen Test (CrAg) – Latex agglutination, ELISA, or lateral flow immunoassay; highly sensitive and specific.
1→3)-β-D-beta-Glucan (BDG) assay
(1,3)-β-D-glucan (BDG) is a specific polysaccharide component in the cell wall of most fungi. Upon systemic or disseminated infection, soluble BDG can be released into blood and tissues. The quantitative detection of BDG in serum is known as BDG assay, serving as a valuable biomarker of invasive fungal disease (Gow et al., 2017). While fungal culture usually needs several days, this assay only takes about one hour, providing clinicians with evidence for early diagnostics of invasive fungal disease, which allows timely provisional treatment of the patient. The BDG assay is frequently used in screening of infections caused by prevalent fungal diseases, caused by species of Candida, Pneumocystis, Aspergillus and others (WHO, 2025). However, fungal colonization of respiratory systems, soft tissues and burn wounds, and venous catheters, as well as contact with materials containing a BDG component all may lead to a raise in serum BDG concentration, resulting in false positivity of the assay; this must be carefully considered when interpreting the assay (Finkelman, 2020).

Fig. 1. The structural components of the fungal cell wall comprise chitin, glucans, and glycoproteins. While variations exist between species, these components are generally arranged as depicted. Most chitin is situated adjacent to the plasma membrane. β-1,3-Glucan forms a network along the entire cell wall. Glycoproteins undergo extensive modification with both N-linked and O-linked oligosaccharides. Many glycoproteins possess GPI (glycosylphosphatidylinositol) anchors that bind them to the plasma membrane. The integration of proteins, glucans, and chitin into the wall occurs through the cross-linking of chitin fibers, glucan chains, protein-bound oligosaccharides, and GPI anchors.
Method
The BDG assay evolved from the LAL (Limulus Amebocyte Lysate) technology. It utilizes the phenomenon that the blue blood reagent from the Horseshoe crab (Limulus polyphemus or Tachypleus tridentatus) coagulates when it is brought in contact with endotoxin or BDG (Tran & Beal, 2016; Tamura et al., 2021). Denaturated single glucan strands are required to perform the test, based on activation of the α-subunit of a G-protein. Native BDG molecules mostly appear as multiple strands of triple helices, which are converted to single strand molecules by alkaline prior to BDG measurement. The BDG detection reagent Limulus amebocyte lysate contains the required G-protein that reacts with BDG and is inactivated to increase the specificity of BDG determination. In the presence of BDG, factor G is activated, leading to a cascade of pre-clotting enzyme activation and transformation of coagulogen to coagulin that can be detected by turbidimetry (Nyuykonge et al., 2023). Another BDG method uses a chromogenic substance of peptide conjugated p-nitroanilide and the activated clotting enzyme releases the p-nitroanilide, a yellow compound can be detected by 405 nm spectrophotometry (d’Ordine et al., 2021). Kinetic turbidimetry and kinetic spectrophotometry can increase the measurement accuracy. This serum BDG assay is an established since decades.

Fig. 2. Limulus amebocyte lysate cascade in the BDG assay.
Several BDG assays are commercially available and are widely used in invasive fungal diseases (IFDs). Frequently applied test kits include Fungitell® Assay and Fungitell STAT® (Associates of Cape Cod, U.S.A.), Wako β-Glucan Test (Fujifilm, Japan), Fungus BDG (Dynamiker, China), Goldstream® Fungus (1-3)-β-D- Glucan Detection kit (ERA Biology, China); BGStar β-Glucan Test (Maruha, Japan) and FungiXpert® Fungus (1-3)-beta-D-Glucan Detection Kit (ERA Biology, China). Fungitell is a commonly used kit in hospital settings; its test procedure is depicted in the diagram below (Fig. 3).

Fig. 3. Procedure of Fungitell assay.

Fig. 4. Protocol of Fungitell assay.
Cutoff values (Table 1) are suggested by manufacturers of commercial systems. The positivity cutoff value for invasive fungal disease may be increased or decreased under particular conditions; corresponding specificity values become higher or lower while sensitivity becomes lower or higher. These cutoff values are suggested by manufacturers of commercial systems. The positivity cutoff value for invasive fungal disease may be increased or decreased in several circumstances and the corresponding specificity values become higher or lower but the sensitivity becomes lower or higher.
Numerous potential causes of false BDG positivity have been reported (Table 2). The filters used for blood products may contain BDG. Infusion of blood products and antibiotics usually show very rapid rise and fall of serum BDG subsequent to administration (Finkelman, 2020).
Table 1. BDG assay products and positivity threshold for the diagnosis of invasive fungal disease.
| Name | Company | Method | Negative (pg/mL) | Intermediate (pg/mL) | Positive (pg/mL) |
| Fungitell | Associates of Cape Cod (U.S.A.) | Spectrophotometer, 405 nm | <60 | 60−80 | >80 |
| Fingus BDG | Dynamiker (China) | Spectrophotometer, 405 nm | <70 | 70−95 | >95 |
| Wako-BDG | Fujifilm Wako (Japan) | Turbidimeter | <5 | 5−11 | >11 |
Table 2. Possible causes of false positive BDG assays.
| Iatrogenic | Infusion of blood products (plasma, albumin, immunoglobulin, coagulation factors) |
| Blood transfusion | Antibiotics (e.g. amoxicillin-clavulanic acid, cefazolin, cefotaxime, trimethoprim-sulfamethoxazole) |
| Hemodialysis | |
| Gauze | |
| Abdominal surgery | |
| Other disease | Bacteremia; Nocardia infection |
| Burn | |
| Hepatitis | |
| Intestinal disease | Intestinal ischemia, severe mucositis or enterocolitis |
| Serum sample | Hemolyzed blood; higher triglycerides; jaundice; container contaminated by DBG and endotoxin |
Clinical significance
BDG assay is useful to detect almost all medically important fungal infections, such as infected by species of Candida, Aspergillus, Fusarium, Pneumocystis, Histoplasma, and Blastomyces (filamentous), with the exception of Cryptococcus species, the yeast phase of Blastomyces dermatitidis, and the Mucorales (Lichtheimia, Mucor, Rhizopus), which are known to have little or no BDG (Table 3; Gow et al., 2017).
see Kostka, E., Le Govic, Y., Damiani, C., & Totet, A. (2024). Variable reliability of the (1,3)-β-d-glucan test for screening Pneumocystis pneumonia in HIV-negative patients depending on the underlying condition. Medical mycology, 62(11), myae106. https://doi.org/10.1093/mmy/myae106
Table 3.Comparative overview of major cell wall components in medically significant fungi and their BDG status.
| Genus | BDG presence / status in cell wall | Expected test result | Clinical utility / notes |
| Candida | Major component | Positive | High utility for diagnosis of invasive infection. |
| Aspergillus | Major component | Positive | High utility for invasive infection. Often used in conjunction with Galactomannan (GM) for increased sensitivity and specificity. |
| Pneumocystis | Major component | Positive | High utility for PCP, especially in HIV / immunocompromised patients. |
| Coccidioides | Major component | Positive | Useful for invasive infection, although serology is also critical. |
| Acremonium | Major component | Positive | Useful for invasive infection, as part of general IFI screening. |
| Fusarium | Major component | Positive | Useful for invasive infection, as part of general IFI screening. |
| Histoplasma | Present (but variable exposure / detection in blood) | Variable (often positive, but can be negative/ weak in disseminated disease) | Useful but variable. Antigen test (e.g. urine antigen) is often more sensitive. |
| Cryptococcus | Present in cell wall, but masked by capsule | Negative / low | Not useful because of capsule. Cryptococcal Antigen (CrAg) detection is the preferred method. |
| Talaromyces | Minimal or absent | Negative | Not useful. |
| Blastomyces | Minimal or absent (especially in yeast phase) | Negative | Not useful. Yeast in tissue contains α-(1,3)-glucan and has minimal exposed β-(1,3)-glucan. |
| Mucorales (Lichtheimia, Mucor, Rhizopus) | Minimal or absent | Negative | Not useful. |
BDG is primarily used in Candida and filamentous ascomycetes. Negative BDG result can help rule out other IFIs and may raise suspicion for mucormycosis. In case of negative test results, diagnosis relies on direct microscopy, culture, MALDI-ToF and specific molecular tests. Invasive fungal disease, in particular invasive candidiasis and invasive aspergillosis, are frequent in patients with leukemia, undergoing hematopoietic stem cell transplantation, organ transplant recipients, and critically ill ICU patients and those under antirejection therapy (Lamoth et al., 2021).
Positive BDG assay often appears positive several days before the clinical diagnosis is made. The BDG assay has been included as a mycological criterion for diagnosing IFD in the European Organization for Research and Treatment of Cancer (EORTC) and Mycoses Study Group (MSG) definitions since 2008 (de Pauw et al., 2008). In the revised and updated definitions in 2019, EORTC/ MSG considered the BDG assay as evidence parameter of probable IFD. This implies that in the condition of two or more serum BDG levels of reaching ≥80 ng/L (Fungitell) are required for diagnosing probable Pneumocystis jirovecii pneumonia and a single threshold of >80 pg/mL (Fungitell ) for diagnosing probable Candida infection (Donnelly et al., 2020). An American Thoracic Society Clinical Practice Guideline mentioned that BDG assays lack utility in the diagnosis of invasive candidiasis (IC) but may be valuable when companied with clinical risk determination and microbiological evidence in identifying patients at risk for IC (Hage et al., 2019).
Using Fungitell kit with >80 pg/mL as the cutoff value, most studies showed that the specificity for the detection of invasive fungal disease was >90% and sensitivity 60-80%. A meta-analysis including 16 studies with 2,979 patients found an average specificity of 85.3% and sensitivity of 76.8% (Karageorgopoulos et al., 2011). The negative predictive value was high (~95%), indicating that negative test results suggest a lower probability of invasive fungal disease; the positive predictive value was relatively low (~60-80%), highlighting the exclusion of false positive BDG assay before evaluating the result. beta-Glucan cannot be metabolized in the body. BDG levels decrease only slowly in the body, even in patients that respond to antifungal therapy. Therefore, repeated BDG assay within a short period of time is recommended for confirming invasive fungal disease, but is not recommended for monitoring response to antifungal therapy.
Galactomannan (GM) assay
Galactomannan (GM) is another polysaccharide component on the outer layer of the cell wall. It is a prevalent compound in numerous filamentous ascomycetes, such as species of Aspergillus, Fusarium, Histoplasma and Scedosporium. Similar to BDG, GM acts as an antigen and can be detected in samples from the bloodstream and tissues during infection. It is utilized by clinicians as an instant and reliable biomarker for auxiliary diagnosis of invasive aspergillosis (IA)(Kovanda et al., 2017). GM performs yields better sensitivity and specificity in IA than BDG, especially in monitoring infection in high-risk patients, e.g. those with hematologic disorders, critical illness, malignancies, and organ transplant recipients. The test facilitates differential diagnosis and can be used in early stages of infection. While GM can be detected in serum, BALF and urine, simultaneous testing of serum and BALF for galactomannan (GM) is an option that is commonly chosen by clinicians to enhance the accuracy of diagnosis. At the same time, various factors, such as concomitant infection by other fungi, certain food intakes, or medical interventions may lead to falsely positive result, which must be carefully considered when interpreting the assay.
Fig. 5. Method of galactomannan assay.
Fig. 6. Protocol of galactomannan assay.
Method
With sufficient immunogenicity exhibited by galactomannan, antibody-based detection is enabled with a rat monoclonal antibody EBA-2 (targeting β-(1-5)-galactofuranose residues). In Aspergillus, these residues are unique linear polymers, and hence are a suitable diagnostic target. Enzyme-Linked Immunosorbent Assay (ELISA) is the most widely used technology for GM detection. ELISA utilizes the highly specific binding reaction between antigen and antibody, coupled with enzymatic catalysis of substrates to generate detectable signals visible as a color change. This method enables qualitative and quantitative detection of GM. Sandwich ELISA is preferred, yielding quantitative detection with a sensitivity of ≤1 ng/mL (Fig. 1).
Commercially available GM assays are widely applied in the diagnosis of invasive aspergillosis. In a WHO recommendation (WHO, 2025), commercially available kits include: PlateliaTM Aspergillus Ag (Bio-Rad, France) for serum and bronchoalveolar lavage fluid, Clarus Aspergillus GM-EIA (IMMY, Norman, OK, U.S.A.) for serum and BALF; Aspergillus Antigen ELISA (Euroimmun, Lübeck, Germany) for serum and BALF; Dynamiker Aspergillus Galactomannan (Dynamiker, Tianjin, China) for serum and BALF; MycoMEIA® Aspergillus Assay (Pearl Diagnostics, Baltimore, MD, U.S.A.) for urine and Clarus Histoplasma GM Enzyme Immunoassay (IMMY) for urine.
Table 4 shows cutoff values recommended by manufacturer (Bio-Rad, 2023) and clinical guidelines are listed in Table 5. It is important to note that the optimal cutoff value may vary depending on the patient population, the type of sample, and the clinical context, influencing the sensitivity and specificity of the assay. Numerous potential causes of false GM positivity have been reported (Table 5). These can generally be categorized into factors related to diet, co-existing conditions, treatments, and laboratory procedures.
Table 5. Thresholds of positive GM for the diagnosis of IA.
| Commercial name | Company | Method | Positive (ODI) | Inderterminate (ODI) | Positive (ODI) |
| Platelia Aspergillus | Bio-Rad | Sandwich ELISA 450 nm | <0.5 <0.5 | 0.5-<0.7 serum 0.5-<1 BALF | ≥7 serum ≥1 BALF |
| Table 6. Possible causes of false positive GC assay. | |
| Iatrogenic | Infusion of blood products (plasma, albumin, immunoglobulin, coagulation factors); antibiotics (e.g. amoxicillin-clavulanic acid); certain cotton swabs |
| Other diseases | Multiple myeloma (hyperproteinemia); intestinal ischemia, severe mucositis, enterocolitis; other fungi (e.g. Histoplasma); autoimmune diseases (e.g. hepatitis, rheumatoid factor) |
| Serum sample | Hemolyzed blood; higher triglycerides; jaundice |
| Food | Certain milk formulations; certain cereals |
Clinical significance
The GM assay is crucial for the diagnosis of invasive aspergillosis (IA), especially in immunocompromised patients such as those undergoing hematopoietic stem cell transplantation, solid organ transplant recipients, and leukemia patients. It is particularly valuable as Aspergillus species are one of the most common causes of mold infections in these populations. Unlike culture-based methods, the GM assay can detect invasive aspergillosis several days before clinical signs become evident, allowing for earlier initiation of antifungal therapy.
The European Organization for Research and Treatment of Cancer (EORTC) and the Mycoses Study Group (MSG) Education and Research Consortium consensus definitions for invasive fungal disease (de Pauw et al., 2008) have incorporated the GM assay as a mycological criterion. In the 2019 revision (Donnelly et al., 2020), a positive GM assay in serum or BALF, depending on the context, contributes to the diagnosis of probable IA. For serum, two positive samples with an ODI of ≥0.5 (or one positive sample with an ODI ≥0.7) are considered significant in high-risk patients. For BALF, an ODI of ≥1.0 is considered a strong indicator.
The European Society for Clinical Microbiology and Infectious Diseases (ESCMID), the European Confederation of Medical Mycology (ECMM) and the European Respiratory Society (ERS) Joint Clinical Guidelines recommended that serum and BALF galactomannan measures are to be used as markers for the diagnosis of IA (Ullmann et al., 2018) Studies consistently show high specificity and variable sensitivity for the GM assay in diagnosing IA. For instance, a meta-analysis on serum GM for IA diagnosis reported a sensitivity ranging from 71% to 88% and a specificity from 89% to 99% (Patterson et al., 2016). The high negative predictive value of the GM assay means that a negative result can effectively rule out IA in many clinical settings, thus potentially reducing unnecessary antifungal treatment. Conversely, the positive predictive value can be influenced by the prevalence of IA in the population and the presence of false positives, necessitating careful interpretation in conjunction with clinical context and imaging findings. Monitoring GM levels over time can also be useful to assess response to antifungal therapy, as declining GM levels often correlate with successful treatment, although its role in routine monitoring is still debated and often depends on clinical guidelines.
Antibody Detection
Complement Fixation Test (CFT) – Used for Histoplasma, Coccidioides, Blastomyces.
Immunodiffusion (ID) – Detects specific precipitin bands (e.g., Coccidioides, Histoplasma).
Counterimmunoelectrophoresis (CIE) – Faster than ID, increases sensitivity.
Enzyme-Linked Immunosorbent Assay (ELISA) – Commonly used for Candida, Aspergillus, Histoplasma.
Latex Agglutination Test – Used for Cryptococcus antibody detection (less common, antigen detection is preferred).
Indirect Immunofluorescence Assay (IFA) – Detects antibodies against fungal antigens.
3. Other Serological/Immunological Approaches
Western Blotting – Used for confirmatory antibody detection in some fungi.
Radioimmunoassay (RIA) – Rarely used today, replaced by ELISA.
Multiplex immunoassays (e.g., Luminex-based tests) – Newer, allow simultaneous detection of multiple fungal antigens/antibodies.

